SPACs back from brink with NK cell therapy biotech’s plans for blank-check merger
Fierce Biotech March 24, 2023
By James Waldron
Graf Acquisition Corp. IV is just the latest in a string of blank-check companies serial special purpose acquisition company founder James Graf has set up. (Andrii Yalanskyi/Getty Images)
After a number of high-profile special purpose acquisition company announcements toward the end of last year, these deals once again dropped off in 2023. But that doesn’t mean the low-key revival of this reverse merger model has died.
Case in point is NKGen Biotech, a natural killer (NK) cell therapy-focused company, which announced plans
to go public via a merger with blank-check company Graf Acquisition Corp. IV. Santa Ana, California-based NKGen was set up in 2017 with a focus on neurodegenerative diseases and oncology and is now led by